A randomized controlled pilot study of daily intravenous ketamine over three days for treatment-resistant depression.

ABSTRACT:

Background

Studies have confirmed the rapid antidepressant action of ketamine in depressive episodes. Nevertheless, a standardized procedure for the delivery of ketamine infusion in individuals suffering from treatment-resistant depression, particularly in terms of infusion frequency and total dosage, remains undetermined. In addition, an efficacious ketamine regimen for persistent pain management involved a continuous 10-day infusion period with no notable adverse effects. Consequently, the primary objective of this study was to evaluate the antidepressant capacity of consecutive ketamine infusions spanning over three successive days, the duration of therapeutic response, and the overall safety profile of the treatment.

Methods

In this randomized controlled trial, participa

SUBMITTER: Pattanaseri K 

PROVIDER: S-EPMC11256507 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature